Clinical Trial Update: Exploring the Safety And Tolerability of Doses of E2007 up to a Maximum of 12 mg In Patients With Refractory Partial Seizures [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and tolerability of E2007 up to 12 mg in patients with refractory partial seizures; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• E2007

Snippet

Sponsor: Eisai Co., Ltd. | Conditions: Epilepsy | Phase 2 | Status: COMPLETED | Results posted: 2012-11-22